Clinical Trials Browser

INDUSTRY × magrolimab × Clear all

NCT03869190 2026-01-22

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Phase 1/2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04854499 2025-11-19

ELEVATE HNSCC

Phase 2 Terminated

193 enrolled 27 charts

Squamous Cell Carcinoma of Head and Neck

NCT04958785 2025-11-04

ELEVATE TNBC

Phase 2 Terminated

92 enrolled 27 charts

Triple Negative Breast Neoplasms

NCT05330429 2025-07-01

ELEVATE CRC

Phase 2 Terminated

77 enrolled 22 charts

Gastrointestinal

Colorectal Neoplasms

NCT02953509 2025-05-29

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Phase 1/2 Terminated

178 enrolled 33 charts

Lymphoma, Non-Hodgkin

NCT04827576 2025-05-08

ELEVATELung&UC

Phase 2 Terminated

106 enrolled 22 charts

Other solid neoplasm

Solid Tumor

NCT04892446 2025-05-02

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Phase 2 Terminated

36 enrolled 17 charts

Multiple Myeloma

NCT05079230 2025-04-04

ENHANCE-3

Phase 3 Terminated

378 enrolled 29 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04778410 2025-03-20

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

Phase 2 Terminated

54 enrolled 26 charts

Myeloid Malignancies

NCT04778397 2025-02-05

ENHANCE-2

Phase 3 Terminated

258 enrolled 25 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06532344 2024-11-14

An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06540261 2024-09-19

The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer

Phase 1 Active not recruiting

Gastrointestinal

Unresectable Colorectal Cancer

NCT05367401 2024-04-11

A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

Phase 1/2 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT03558139 2024-04-01

Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy

Phase 1 Completed

34 enrolled 17 charts

Ovarian Neoplasms

NCT05627466 2024-02-15

US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia

No longer available

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03527147 2022-08-15

PRISM

Phase 1 Completed

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03922477 2022-02-21

A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Phase 1 Terminated

13 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02953782 2021-03-01

Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer

Phase 1/2 Completed

78 enrolled 27 charts

Gastrointestinal

Colorectal Neoplasms

NCT02678338 2019-02-21

CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies

Phase 1 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02216409 2019-02-05

Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody

Phase 1 Completed

Other solid neoplasm

Solid Tumor